| Drug Type Small molecule drug | 
| Synonyms- | 
| Target | 
| Action modulators | 
| Mechanism Cholesterol modulators | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 2 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Meibomian Gland Dysfunction | Phase 2 | United States  | 05 Sep 2021 | 
| Phase 2 | 92 | (CBT-006 Lower Concentration) | vtblpfhexp(lpopddmndp) = zjoeamtxcs pdcvnthmod  (tvywtqjwzf, 2.6230) View more | - | 24 Apr 2024 | ||
| (CBT-006 Higher Concentration) | vtblpfhexp(lpopddmndp) = wdikzmbuza pdcvnthmod  (tvywtqjwzf, 2.6647) View more | 





